فهرست نشریات علمی دسترسی آزاد ایران

Treated in breast cancer depends on how advanced the cancer is, so the way the treatment of the cancer may use drugs, operation, or radiation treatment. However, all these lead to unwanted effects including chemotherapy and radiation. It is critically essential to recognize new therapeutic targets and produce efficient, targeted therapies. The development of methotrexate-linked zinc oxide nanoparticles (MTX-ZnONPs) and their potent anti-breast cancer cell properties are investigated in this study. Using various method such as UV visible spectroscopy, Dynamic light scattering (DLS), Scanning electron microscopy (SEM) and Scanning electron microscopy (SEM) we have confirmed the linking of ZnONPs with MTX. We also treated MCF7 cells with MTX-ZnONPs in a laboratory setting in order to test the effectiveness of MTX-ZnONPs, and found out how it behaves using the MTT assay. Then, to confirm the cytotoxic effect, further investigation is needed to investigate the cytotoxic effects and the expression levels of two key genes, P53 and COX-2. MTX and MTX-ZnONPs were expressed at different levels in both genes and compared to expression of the control group. As indicators of oxidative stress, the malondialdehyde (MDA) level was also measured. The MTT assay findings demonstrated that both free MTX and MTX-ZnONPs were efficient at causing cytotoxic effects on MCF7 cells. Increased gene expression of P53 and COX-2 was noted in cells when treated with MTX-ZnONPs or MTX instead of the control group, possibly indicating potential therapy. As a marker of oxidative stress, levels of malondialdehyde (MDA) were also measured and there was a significant increase in MTX-ZnONPs and MTX compared to controls, MTX and MTX-ZnONPs, respectively. As a result, our findings demonstrated the excellent efficacy of MTX-ZnONPs, suggesting that ZnONPs function as nanocarriers to deliver the medication intracellularly.